A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Complement-Mediated Kidney Disease
Спонсор: Adarx Pharmaceuticals Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time
Incidence and severity of TEAEs
Описание
1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 7 participants
БГ
EN